Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) EBIAT (2016 - 2025)

Coherus Oncology's EBIAT history spans 13 years, with the latest figure at -$46.3 million for Q4 2025.

  • For Q4 2025, EBIAT rose 8.58% year-over-year to -$46.3 million; the TTM value through Dec 2025 reached $150.3 million, up 427.36%, while the annual FY2025 figure was $168.0 million, 489.41% up from the prior year.
  • EBIAT for Q4 2025 was -$46.3 million at Coherus Oncology, down from -$44.5 million in the prior quarter.
  • Across five years, EBIAT topped out at $297.8 million in Q2 2025 and bottomed at -$172.9 million in Q1 2021.
  • The 5-year median for EBIAT is -$46.0 million (2021), against an average of -$31.9 million.
  • The largest annual shift saw EBIAT tumbled 586.19% in 2021 before it soared 2404.52% in 2025.
  • A 5-year view of EBIAT shows it stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then tumbled by 35.3% to -$79.7 million in 2023, then soared by 36.35% to -$50.7 million in 2024, then grew by 8.58% to -$46.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EBIAT are -$46.3 million (Q4 2025), -$44.5 million (Q3 2025), and $297.8 million (Q2 2025).